Direct-acting antivirals and hepatocellular carcinoma occurrence and recurrence in hepatitis C virus-related liver cirrhosis: fact or fiction

作     者：Alberto Zanetto Sarah Shalaby Alberto Ferrarese Chiara Becchetti Salvatore Sciarrone Giacomo Germani Marco Senzolo Martina Gambato Francesco Paolo Russo Patrizia Burra 

作者机构：Multivisceral Transplant UnitDepartment of SurgeryOncology and GastroenterologyPadua University HospitalPadua 35128Italy 

出 版 物：《Hepatoma Research》 (肝癌研究（英文版）)

年 卷 期：2018年第4卷第11期

页      面：16-31页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Hepatitis C virus direct-acting antiviral agent occurrence recurrence hepatocellular carcinoma and liver cirrhosis 

摘      要：Since the widespread adoption of new direct-acting antiviral agents (DAAs), the approach to hepatitis C virus (HCV) infection has changed profoundly as almost all patients can be cured regardless of the stage of their liver disease. On the other hand, there are a few conflicting reports on the risk of hepatocellular carcinoma (HCC) occurring and recurring in patients given DAA-based therapy. The present review focuses on the latest and most relevant literature providing evidence on the occurrence and recurrence of HCC after HCV antiviral treatment with the new DAAs. Retaining the distinction between HCC occurrence and recurrence, we also discuss its patterns of presentation and speculate on the possible pathogenic mechanisms. We offer our personal viewpoints on this important issue, which has kept clinicians second-guessing in real-world clinical practice, when dealing with HCV eradication in the setting of advanced liver disease in this interferon-free era.